GARY PATOU, a director at $XENE, sold 1,322 shares of the company on 06-05-2026 for an estimated $70,251. We received data on the trade from a recent SEC filing. This was a sale of approximately 5.0% of their shares of this class of stock. Following this trade, they now own 24,896 shares of this class of $XENE stock.
$XENE Insider Trading Activity
$XENE insiders have traded $XENE stock on the open market 19 times in the past 6 months. Of those trades, 0 have been purchases and 19 have been sales.
Here’s a breakdown of recent trading of $XENE stock by insiders over the last 6 months:
- IAN MORTIMER (PRESIDENT & CEO) has made 0 purchases and 13 sales selling 328,577 shares for an estimated $19,147,176.
- CHRISTOPHER JOHN KENNEY (Chief Medical Officer) has made 0 purchases and 2 sales selling 4,181 shares for an estimated $244,426.
- ANDREA DIFABIO (Chief Legal Officer) has made 0 purchases and 2 sales selling 3,949 shares for an estimated $230,813.
- GARY PATOU sold 1,322 shares for an estimated $70,251
- GILLIAN CANNON sold 1,190 shares for an estimated $63,236
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$XENE Hedge Fund Activity
We have seen 196 institutional investors add shares of $XENE stock to their portfolio, and 104 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POLAR CAPITAL HOLDINGS PLC added 1,939,618 shares (+78.7%) to their portfolio in Q1 2026, for an estimated $112,788,786
- FMR LLC added 1,898,241 shares (+21.3%) to their portfolio in Q1 2026, for an estimated $110,382,714
- BRAIDWELL LP removed 1,779,953 shares (-49.4%) from their portfolio in Q4 2025, for an estimated $79,777,493
- CITADEL ADVISORS LLC added 1,331,777 shares (+100.8%) to their portfolio in Q1 2026, for an estimated $77,442,832
- ALYESKA INVESTMENT GROUP, L.P. added 1,299,469 shares (+inf%) to their portfolio in Q1 2026, for an estimated $75,564,122
- COMMODORE CAPITAL LP removed 975,000 shares (-54.2%) from their portfolio in Q1 2026, for an estimated $56,696,250
- CALIGAN PARTNERS LP added 843,362 shares (+153.4%) to their portfolio in Q1 2026, for an estimated $49,041,500
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$XENE Analyst Ratings
Wall Street analysts have issued reports on $XENE in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 05/08/2026
To track analyst ratings and price targets for $XENE, check out Quiver Quantitative's $XENE forecast page.
$XENE Price Targets
Multiple analysts have issued price targets for $XENE recently. We have seen 9 analysts offer price targets for $XENE in the last 6 months, with a median target of $78.0.
Here are some recent targets:
- Tessa Romero from JP Morgan set a target price of $82.0 on 05/27/2026
- Serge Belanger from Needham set a target price of $78.0 on 05/08/2026
- Brian Abrahams from RBC Capital set a target price of $82.0 on 05/08/2026
- Laura Chico from Wedbush set a target price of $63.0 on 03/16/2026
- David Hoang from Deutsche Bank set a target price of $90.0 on 03/10/2026
- Douglas Tsao from HC Wainwright & Co. set a target price of $74.0 on 03/10/2026
- Benjamin Burnett from Wells Fargo set a target price of $68.0 on 03/10/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
